{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:13:32Z","timestamp":1783102412103,"version":"3.54.6"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Plasma-derived \u03b2-amyloid, tau, and neurodegeneration (ATN) biomarkers can accurately diagnose Alzheimer\u2019s disease (AD) and predict its progression. Few studies have investigated the relationship between plasma biomarkers and changes in plasma inflammatory markers in clinically diagnosed AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Seventy-four participants were recruited, including 30 mild-to-moderate AD dementia patients and 44 normal controls (NC). All participants underwent neuropsychological testing and blood sampling for biomarker testing. AD was clinically diagnosed according to the National Institute on Aging-Alzheimer\u2019s Association (NIA-AA) core criteria and required age-mismatched hippocampal atrophy. We performed Single Molecule Array (Simoa), an ultra-sensitive enzyme-linked immunosorbent assay (ELISA), to examine plasma ATN markers, including \u03b2-amyloid (A\u03b2) 40, A\u03b242, p-tau181, total (t)-tau, neurofilament protein light chain (NfL), and inflammatory factors (TNF-\u03b1, IL-1\u03b2, IL-6, and IL-8).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The level of the plasma A\u03b242\/A\u03b240 ratio was significantly declined and the levels of the plasma p-tau181, NfL and TNF-\u03b1 were significantly higher in the AD group than the NC group, but there was no significant difference in the levels of plasma t-tau, IL-1\u03b2, IL-6, and IL-8 between the AD and NC groups. The levels of plasma p-tau181, NfL, A\u03b242\/A\u03b240 ratio, and TNF-\u03b1 were all associated with impairments in multiple cognitive domains. Among them, the plasma A\u03b242\/A\u03b240 ratio, and the p-tau181 and TNF-\u03b1 levels were associated with impairments in global cognition, memory, and visuospatial abilities, but not with executive function, only plasma NfL level was associated with executive function. Plasma NfL showed higher diagnostic performance in AD than in NC individuals (AUC = 0.833). A combined diagnostic prediction model of plasma A\u03b242\/A\u03b240 ratio, p-tau 181, and NfL had the highest value than each factor alone (AUC = 0.902),with a sensitivity and specificity of 0.867 and 0.886, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The levels of plasma ATN biomarkers (A\u03b242\/A\u03b240 ratio, p-tua181, and NfL) were significantly changed in clinically diagnosed AD patients and they all associated with different domains of cognitive impairment. Plasma ATN biomarkers better differentiate mild-to-moderate AD dementia from NC when they are incorporated into diagnostic models together rather than individually. Plasma ATN biomarkers have the potential to be a screening tool for AD. However, the expression of inflammatory factors in AD patients requires further research.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnagi.2022.963845","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T06:39:18Z","timestamp":1660804758000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Plasma \u03b2-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer\u2019s disease dementia in Chinese individuals"],"prefix":"10.3389","volume":"14","author":[{"given":"Qingling","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnian","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhou","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"B1","year":"2018","journal-title":"World Alzheimer report 2018."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study.","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimers Dement."},{"key":"B3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s12035-014-8657-1","article-title":"Body fluid cytokine levels in mild cognitive impairment and Alzheimer\u2019s disease: A comparative overview.","volume":"50","author":"Brosseron","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3233\/JAD-180025","article-title":"Association of plasma neurofilament light chain with neocortical amyloid-\u03b2 load and cognitive performance in cognitively normal elderly participants.","volume":"63","author":"Chatterjee","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0532-x","article-title":"Discordant amyloid-\u03b2 PET and CSF biomarkers and its clinical consequences.","volume":"11","author":"de Wilde","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00702-017-1773-0","article-title":"Genome-wide significant, replicated and functional risk variants for Alzheimer\u2019s disease","volume":"124","author":"Guo","year":"2017","journal-title":"J. Neural Transm."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)62274-X","article-title":"Auguste D and Alzheimers disease.","volume":"350","author":"Gurwitz","year":"1997","journal-title":"Lancet (Lond. Engl.)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-91038-0","article-title":"Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults.","volume":"11","author":"He","year":"2021","journal-title":"Sci. Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1212\/WNL.0b013e318225ae07","article-title":"Proinflammatory cytokines, sickness behavior, and Alzheimer disease.","volume":"77","author":"Holmes","year":"2011","journal-title":"Neurology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1192\/bjp.140.6.566","article-title":"A new clinical scale for the staging of dementia.","volume":"140","author":"Hughes","year":"1982","journal-title":"Br. J. Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1212\/WNL.0000000000011226","article-title":"Plasma Tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease.","volume":"96","author":"Ill\u00e1n-Gala","year":"2021","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13854049208401877","article-title":"Wais-r, wms-r and avlt norms for ages 56 through 97.","volume":"6","author":"Ivnik","year":"1992","journal-title":"Clin. Neuropsychol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research framework: Toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia.","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3233\/JAD-171131","article-title":"Blood inflammatory mediators and cognitive decline in Alzheimer\u2019s disease: A two years longitudinal study.","volume":"63","author":"Julian","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"170","DOI":"10.14336\/AD.2014.0500170","article-title":"Raised serum proinflammatory cytokines in Alzheimer\u2019s disease with depression.","volume":"5","author":"Khemka","year":"2014","journal-title":"Aging Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011146","article-title":"Prevalence and determinants of undetected dementia in the community: A systematic literature review and a meta-analysis.","volume":"7","author":"Lang","year":"2017","journal-title":"BMJ Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","article-title":"Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline.","volume":"140","author":"Lantero Rodriguez","year":"2020","journal-title":"Acta Neuropathol."},{"key":"B21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: Self-maintaining and instrumental activities of daily living.","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0404-9","article-title":"Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease.","volume":"10","author":"Lewczuk","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40120-017-0074-8","article-title":"Amyloid beta and Tau as Alzheimer\u2019s disease blood biomarkers: Promise from new technologies.","volume":"6","author":"Lue","year":"2017","journal-title":"Neurol. Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients With Alzheimer disease.","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"B26","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/gps.4317","article-title":"Screening mild cognitive impairment by delayed story recall and instrumental activities of daily living.","volume":"30","author":"Ni","year":"2015","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: A systematic review and meta-analysis.","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00245","article-title":"Blood-cerebrospinal fluid barrier gradients in mild cognitive impairment and Alzheimer\u2019s disease: Relationship to inflammatory cytokines and chemokines.","volume":"10","author":"Ott","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.neurobiolaging.2017.06.002","article-title":"Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer\u2019s disease.","volume":"58","author":"Pereira","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/jnnp-2020-325537","article-title":"Associations of longitudinal plasma p-tau181 and NfL with tau-PET, A\u03b2-PET and cognition.","volume":"92","author":"Rauchmann","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/jnnp-2018-319148","article-title":"Inflammatory markers in Alzheimer\u2019s disease and mild cognitive impairment: A meta-analysis and systematic review of 170 Shen studies.","volume":"90","author":"Shen","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-14-71","article-title":"The Chinese version of story recall: A useful screening tool for mild cognitive impairment and Alzheimer\u2019s disease in the elderly.","volume":"14","author":"Shi","year":"2014","journal-title":"BMC Psychiatry"},{"key":"B33","first-page":"136","article-title":"Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease.","volume":"34","author":"Thomann","year":"2009","journal-title":"J. Psychiatry Neurosci."},{"key":"B34","first-page":"2945","article-title":"Guidelines for the application of brief cognitive tests in the diagnosis of dementia in China","volume":"96","author":"Tian","year":"2016","journal-title":"Chin. Med. J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/brain\/awaa422","article-title":"Concatenating plasma p-tau to Alzheimer\u2019s disease.","volume":"144","author":"Tijms","year":"2021","journal-title":"Brain"},{"key":"B36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.22248","article-title":"Longitudinal assessment of A\u03b2 and cognition in aging and Alzheimer disease.","volume":"69","author":"Villemagne","year":"2011","journal-title":"Ann. Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12264-008-0105-7","article-title":"Alzheimer\u2019s disease: Epidemiology, genetics, and beyond.","volume":"24","author":"Wang","year":"2008","journal-title":"Neurosci. Bull."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-019-1072-8","article-title":"A new age-related cutoff of medial temporal atrophy scale on MRI improving the diagnostic accuracy of neurodegeneration due to Alzheimer\u2019s disease in a Chinese population.","volume":"19","author":"Wei","year":"2019","journal-title":"BMC Geriatr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/2211068215589580","article-title":"The Simoa HD-1 analyzer: A novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing.","volume":"21","author":"Wilson","year":"2016","journal-title":"J. Lab. Autom."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00864-x","article-title":"Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer\u2019s disease.","volume":"13","author":"Xiao","year":"2021","journal-title":"Alzheimers Res. Ther."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.963845\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T06:39:24Z","timestamp":1660804764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.963845\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":40,"alternative-id":["10.3389\/fnagi.2022.963845"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2022.963845","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"article-number":"963845"}}